EUCTR2020-000982-18-NO进行中（未招募）1 期
The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19
Oslo University Hospital0 个研究点目标入组 443 人开始时间: 2020年3月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 443
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Adult patients, 18 years and above
- •2.Confirmed SARS-2-CoV-2 infection by PCR
- •3.Admitted to the hospital ward or the ICU
- •4.Subjects (or legally authorized representative) provides written informed consent prior to initiation of the study
- •5.No anticipated transfer within 72 hours to a non-study hospital
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 221
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 222
排除标准
- •1.Severe co-morbidity with life expectancy <3 months according to investigators assessment
- •2.ASAT/ALAT > 5 times the upper limit of normal
- •3.Acute co-morbidity within 7 days before inclusion such as myocardial infarction
- •4.Known intolerance to the available study drugs
- •5.Pregnancy or breast feeding
- •6.Any reason why, in the opinion of the investigators, the patient should not participate
- •7.Subject participates in a potentially confounding drug or device trial during the course of the study
- •8.Prolonged QT interval (>470 ms)
- •9.Already receiving any of the study drugs
- •10. Hydroxychloroquine should not be given to patients with psoriasis.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).SARS-COV-2 infectionMedDRA version: 21.1Level: LLTClassification code 10037373Term: Pulmonary disorderSystem Organ Class: 100000004855EUCTR2020-000982-18-SEKarolinska University hospital1,218
进行中（未招募）
1 期
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without InhibitorsHaemophilia AMedDRA version: 20.0 Level: LLT Classification code 10018938 Term: Haemophilia A (Factor VIII) System Organ Class: 100000004850EUCTR2016-000614-29-DEovo Nordisk A/S33
进行中（未招募）
1 期
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without InhibitorsHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000011915EUCTR2016-000614-29-FRovo Nordisk A/S33
进行中（未招募）
1 期
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without InhibitorsHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000011915EUCTR2016-000614-29-ESovo Nordisk A/S33
进行中（未招募）
1 期
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without InhibitorsHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2016-000614-29-SEovo Nordisk A/S33